Biotech · Private company

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Track this companyFree. Adds Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) to your Dealase workspace and tells you when its record changes.

Clinical trials103 recruiting or active

Pipeline programs15From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline15

CaspofunginPhase 3 · CandidemiaClinicalTrials.gov · fetched Nov 12, 2026
FluconazolePhase 3 · CandidemiaClinicalTrials.gov · fetched Nov 12, 2026
MK-1406Phase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
Rezafungin for InjectionPhase 3 · CandidemiaClinicalTrials.gov · fetched Nov 12, 2026
CD101Phase 2 · CandidemiaClinicalTrials.gov · fetched Nov 12, 2026
CD101 External gel (1%)Phase 2 · Candidiasis, VulvovaginalClinicalTrials.gov · fetched Nov 12, 2026
CD101 External ointment (1%)Phase 2 · Candidiasis, VulvovaginalClinicalTrials.gov · fetched Nov 12, 2026
CD101 Vaginal Gel (3%)Phase 2 · Candidiasis, VulvovaginalClinicalTrials.gov · fetched Nov 12, 2026
CD101 Vaginal Ointment (6%)Phase 2 · Candidiasis, VulvovaginalClinicalTrials.gov · fetched Nov 12, 2026
CD388 InjectionPhase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
FluconazolePhase 2 · Candidiasis, VulvovaginalClinicalTrials.gov · fetched Nov 12, 2026
MK-1406 InjectionPhase 2 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
CD101 IVPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
CD388 InjectionPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Fluzone® High-Dose (HD) influenza vaccinePhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials10

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)PHASE1 · RECRUITING · started Nov 8, 2025ClinicalTrials.gov NCT07300085 · fetched Nov 12, 2026
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 29, 2025ClinicalTrials.gov NCT07225959 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)PHASE3 · RECRUITING · started Sep 25, 2025ClinicalTrials.gov NCT07159763 · fetched Nov 12, 2026
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza ComplicationsPHASE2 · COMPLETED · started Sep 20, 2024ClinicalTrials.gov NCT06609460 · fetched Nov 12, 2026
Study of CD388 Subcutaneous Administration in Healthy Japanese SubjectsPHASE1 · COMPLETED · started Oct 18, 2022ClinicalTrials.gov NCT05619536 · fetched Nov 12, 2026
Study of CD388 Intramuscular or Subcutaneous Administration in Healthy SubjectsPHASE1 · COMPLETED · started Mar 14, 2022ClinicalTrials.gov NCT05285137 · fetched Nov 12, 2026
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive CandidiasisPHASE3 · COMPLETED · started Oct 7, 2018ClinicalTrials.gov NCT03667690 · fetched Nov 12, 2026
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging ExtensionPHASE2 · COMPLETED · started Jul 26, 2016ClinicalTrials.gov NCT02734862 · fetched Nov 12, 2026
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast InfectionsPHASE2 · COMPLETED · started Jun 8, 2016ClinicalTrials.gov NCT02733432 · fetched Nov 12, 2026
A Single Ascending Dose Study of CD101 IV in Healthy SubjectsPHASE1 · COMPLETED · started Jul 1, 2015ClinicalTrials.gov NCT02516904 · fetched Nov 12, 2026